Clicky

Boundless Bio, Inc. Common Stock(BOLD)

Description: Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.


Keywords:

Home Page: boundlessbio.com

9880 Campus Point Drive
San Diego, CA 92121
United States
Phone: 858 766 9912


Officers

Name Title
Dr. Jonathan E. Lim M.D. Co-Founder & Independent Chairman
Mr. Zachary Hornby CEO, President & Director
Dr. Christian Hassig Ph.D. Chief Scientific Officer
Mr. David Hinkle Senior VP of Finance & Controller
Ms. Jessica Oien J.D. Chief Legal Officer & Corporate Secretary
Mr. Neil Abdollahian M.B.A., M.S. Chief Business Officer
Mr. Anthony Pinkerton Ph.D. Senior Vice President of Drug Discovery
Ms. Meredith Wesley Senior Vice President of Talent & Culture
Dr. Peter Krein Ph.D. Senior Vice President of Precision Medicine
Ms. Amy Berkley Ph.D. Senior Vice President of Program Team

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4457
Price-to-Sales TTM: 0
IPO Date: 2024-03-28
Fiscal Year End: December
Full Time Employees: 72
Back to stocks